Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Giant Biogene Holding CoHKSE:02367 +0.99%85 EBITDA Margin % is 39.12% as of Dec. 2025, which is 23% below its 10-year median of 50.98. GuruFocus rates HKSE:02367 with a GF Score™ of 85/100 and a GF Value™ of HK$68.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,974 Consumer Packaged Goods companies, Giant Biogene Holding Co ranks better than 96.4% on this metric.
Giant Biogene Holding Co (HKSE:02367) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Giant Biogene Holding Co EBITDA Margin % Related Terms
Giant Biogene Holding Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02367 vs PG, CL, EL: EBITDA Margin % Comparison
For the Household & Personal Products subindustry, Giant Biogene Holding Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Giant Biogene Holding Co EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Giant Biogene Holding Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co (HKSE:02367) has a EBITDA Margin % of 39.12% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Giant Biogene Holding Co and its competitors. This is 23% below median its historical median of 50.98. Over the past decade, Giant Biogene Holding Co's EBITDA Margin % has ranged from 38.41 to 72.70. According to the industry distribution chart, Giant Biogene Holding Co ranks #71 out of 1974 companies in the Consumer Packaged Goods industry, placing it in the top 3.6%.
Is Giant Biogene Holding Co's EBITDA Margin % too high?
Giant Biogene Holding Co's current EBITDA Margin % of 39.12% is 23% below median its 10-year median of 50.98. Over the past 10 years, this metric has ranged from a low of 38.41 to a high of 72.70. The Consumer Packaged Goods industry median EBITDA Margin % is 8.92. Giant Biogene Holding Co's value of 39.12% is 338.6% above this industry median. Based on the distribution chart, Giant Biogene Holding Co ranks #71 out of 1974 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's EBITDA Margin % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Giant Biogene Holding Co ranks #71 out of 1974 companies for EBITDA Margin %. This places Giant Biogene Holding Co in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.92. Giant Biogene Holding Co's value of 39.12% is 338.6% above this benchmark. Historically, Giant Biogene Holding Co's own EBITDA Margin % has ranged from 38.41 to 72.70 over the past decade. While the company's 10-year median is 50.98 vs. the industry median of 8.92, Giant Biogene Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.92, based on 1,974 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Giant Biogene Holding Co's current EBITDA Margin % of 39.12% is 338.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Giant Biogene Holding Co and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Giant Biogene Holding Co's current EBITDA Margin % is 39.12%, which is 23% below median its own 10-year median of 50.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.03, compared to a current price of HK$24.40 — trading 64.1% below its estimated fair value. The current EBITDA Margin % is 39.12%, which is 23% below median its 10-year median of 50.98 and 338.6% above the Consumer Packaged Goods industry median of 8.92. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current EBITDA Margin % is 39.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.40 is trading 64.1% below its estimated GF Value™ of HK$68.03.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
EBITDA Margin %: 39.12% (23% below median its 10-year median of 50.98)
GF Value™: HK$68.03 vs. price of HK$24.40 (64.1% below fair value)
Industry Position: 338.6% above the Consumer Packaged Goods median (#71 of 1974)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
